1-14 of 14
Guan Xing
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Characteristics and Overall Survival Among Acute Myeloid Leukemia (AML) Patients with TP53 Gene Mutation (TP53m) or Chromosome 17p Deletion (17p del)

Naval Daver, Shahed Iqbal, Julie Huang, Camille Renard, Joyce Lin, Harry Pan, Guan Xing, Yang Pan, Giri Ramsingh
Journal: Blood
Blood (2022) 140 (Supplement 1): 1445–1446.
https://doi.org/10.1182/blood-2022-170298
Published: 2022
Journal Articles

A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53 -Mutant Acute Myeloid Leukemia

Naval Daver, Paresh Vyas, Mark Chao, Guan Xing, Camille Renard, Giri Ramsingh, David A. Sallman, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 3426.
https://doi.org/10.1182/blood-2021-145208
Published: 2021
Journal Articles

A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia

Paresh Vyas, Naval Daver, Mark Chao, Guan Xing, Camille Renard, Giri Ramsingh, Andrew H. Wei, David A. Sallman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3424.
https://doi.org/10.1182/blood-2021-145584
Published: 2021
Journal Articles

Impact of Idelalisib Treatment Interruption with or without Dose Reduction on Outcomes in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Shuo Ma, MD PhD, Rebecca J Chan, MD PhD, Lin Gu, MS, Guan Xing, PhD, Nishan Rajakumaraswamy, MD, Bianca Ruzicka, PhD, Nina D. Wagner-Johnston, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5468.
https://doi.org/10.1182/blood-2019-124541
Published: 2019
Journal Articles

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Sven de Vos, MD PhD, Gilles A. Salles, MD PhD, Wojciech Jurczak, MD PhD, Nishan Rajakumaraswamy, MD, Guan Xing, PhD, Ajay K. Gopal, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4006.
https://doi.org/10.1182/blood-2019-121936
Published: 2019
Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Yong Mun, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Kari G. Chaffee, MS, Richard R. Furman, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jeff Sharman, MD, John F. Seymour, MBBS, PhD, Asher A. Chanan-Khan, MD, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, Lucille A. Ferrante, MD, Lyndah K. Dreiling, MD, Mehrdad Mobasher, MD MPH, Thomas Stark, MD PhD, Vijay Reddy, MD PhD, Angela J. Howes, BSc, PhD, Danelle James, MD MAS, Pankaj Bhargava, MD, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4394.
https://doi.org/10.1182/blood-2018-99-112989
Published: 2018
Journal Articles

Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma

Farrukh T. Awan, MD MS, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Ajay K. Gopal, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5322.
https://doi.org/10.1182/blood-2018-99-110477
Published: 2018
Journal Articles

Idelalisib Plus Anti-CD20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL

Jennifer R. Brown, MD PhD, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Susan M. O'Brien, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5564.
https://doi.org/10.1182/blood-2018-99-110853
Published: 2018
Journal Articles

Survival Outcomes Following Idelalisib Interruption in the Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Shuo Ma, MD PhD, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Carrie Ellen Brubaker, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Nina D. Wagner-Johnston, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3149.
https://doi.org/10.1182/blood-2018-99-110655
Published: 2018
Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukemi

Vinay Manu Daryani, PharmD, Shringi Sharma, PhD, Guan Xing, PhD, Jeffrey Silverman, PhD, Adeboye Henry Adewoye, MD, Anita Mathias, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5344.
https://doi.org/10.1182/blood.V130.Suppl_1.5344.5344
Published: 2017
Journal Articles

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Julie Huang, PhD, Ming Lin, PhD, John C. Byrd, MD, Asher A. Chanan-Khan, MD, Richard R. Furman, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Jeffrey Jones, MD, Jeffrey P. Sharman, MD, Lucille Ferrante, MD, Vijay Reddy, MD PhD, Lyndah K. Dreiling, MD, Henry Adewoye, MD, Ronald Dubowy, MD, Angela Howes, PhD, Danelle F. James, MD MAS, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4303.
https://doi.org/10.1182/blood.V130.Suppl_1.4303.4303
Published: 2017
Journal Articles

Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Raymond Perez, MD, Rachid Baz, MD, Paul G. Richardson, Kenneth C. Anderson, MD, Peter Sabbatini, PhD, Clifford Dilea, Pina M. Cardarelli, PhD, Mark Wade, Guan Xing, PhD, Andres Gutierrez, MD PhD, Lewis Cohen, MD MS, Pamela S. Becker, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3483.
https://doi.org/10.1182/blood.V124.21.3483.3483
Published: 2014
Journal Articles

Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia

Pamela S. Becker, MD PhD, James M. Foran, MD, Jessica K. Altman, MD, Abdulraheem Yacoub, MD MB, Januario E. Castro, MD, Peter Sabbatini, PhD, Clifford Dilea, Mark Wade, Guan Xing, PhD, Andres Gutierrez, MD PhD, Lewis Cohen, MD MS, B. Douglas Smith, MD
Journal: Blood
Blood (2014) 124 (21): 386.
https://doi.org/10.1182/blood.V124.21.386.386
Published: 2014
Journal Articles

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

Animesh Pardanani, MBBS, PhD, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, FRACP, PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, MD, Kebede Begna, MD, Hiroyuki Yoshitsugu, PhD, Toni Ann Gestone, PhD, Penny Phillips, PhD, Guan Xing, PhD, Gerson Peltz, MD, MPH, Matthew V Lorenzi, PhD, Leila Alland, MD, Adrian Woolfson, BM BCh, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2013) 122 (21): 664.
https://doi.org/10.1182/blood.V122.21.664.664
Published: 2013